Updated Results from the Phase I/II CHAMPION-1 Study of Weekly Carfilzomib with Dexamethasone for Relapsed/Refractory MM
Berenson J et al. Weekly carfilzomib with dexamethasone for patients with relapsed or refractory multiple myeloma: Updated results from the phase 1/2 study Champion-1 (NCT01677858). Proc ASH 2015; Abstract 373.
Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
|